Shelley Glick; Jeff Wisotzkey; Kristina Habermann; Mike Adriani; Rob Gibbs

Feb 18, 2015

Genomind this week announced several new executives. Shelley Glick was named vice president of managed care; Jeff Wisotzkey has joined the company as lab director and VP of molecular pathology; Kristina Habermann is VP of marketing and corporate communications; and Mike Adriani was named SVP of information technology. Also, Rob Gibbs was promoted to the newly created position of chief commercial officer. 

Glick has more than 13 years of experience in the molecular diagnostics space and the medical device industry with a focus on managed care, payer relations, and health economics, Genomind said. Meanwhile, prior to joining the company, Wisotzkey was director of molecular pathology and technical director of laboratory operations at the Central Pennsylvania Alliance Laboratory. 

Habermann was in product management at PerkinElmer's diagnostics division before she joined Genomind, while Adriani was previously VP of IT at Plus Diagnostics. 

Gibbs has held leadership positions at Cigna and at Medecision in sales, marketing, finance, and operations.

More Like This

Apr 17, 2018

Patrick Kaltenbach

Agilent said that Patrick Kaltenbach, senior vice president for the company and president of Agilent's Life Sciences and Analytical Group, will leave the company on April 20. The company did not provide a reason for Kaltenbach's departure. A replacement for his position is underway, Agilent said.

Apr 16, 2018

John Lubniewski

John Lubniewski has been promoted by HTG Molecular Diagnostics to president and chief operating officer. Lubniewski has been the company's chief business officer for the past seven years. He joined HTG from Ventana, now part of Roche, where he held several senior leadership roles, and was responsible for marketing and global accountability for all assay products. Prior to joining Ventana, he was with Corning.

Apr 16, 2018

Richard Williams

Richard Williams has become managing director and head of oncology programs at WuXi Nextcode. He joins the company from Grail, where he was lead medical director of the Circulating Cell-Free Genome Atlas program. Prior to that, he held positions in oncology drug development at Amgen and at Puma Technology. Williams holds B.Med.Sc and PhD degrees, as well as bachelor of medicine and bachelor of surgery degrees, from the University of Queensland in Australia.

Apr 13, 2018

Aleksandar Rajkovic

Aleksandar Rajkovic has become the first chief genomics officer of the University of California, San Francisco. He joins UCSF from the University of Pittsburgh Medical Center, where he was division director of reproductive genetics. In his new role, Rajkovic will direct the activities of UCSF's existing clinical genomics laboratories, in addition to leading efforts to apply genetics and genomics to clinical care within the health system.

Apr 13, 2018

Irwin Jacobs, Martin Wygod

Biological Dynamics has added Irwin Jacobs and Martin Wygod to its board of directors. Jacobs is a cofounder of semiconductor and telecommunications equipment firm Qualcomm, as well as chairman emeritus of the Salk Institute for Biological Studies. Wygod is director of Medco Containment Services and former chairman of WebMD Health. 

Apr 13, 2018

Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, Robin Patel

Curetis has established a US scientific advisory board consisting of five infectious disease experts. Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, and Robin Patel will support the clinical adoption of the firm's Unyvero System and lower respiratory tract infection assay recently cleared by the US Food and Drug Administration. 

Goff is currently an infectious diseases specialist with the One Health Antibiotic Stewardship team at The Ohio State University; Mildvan is professor of medicine at Icahn School of Medicine at Mount Sinai in New York; Miller is director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine; Nolte is medical director of clinical labs and molecular pathology at the Medical University of South Carolina; and Patel is co-director of the clinical bacteriology laboratory, director of the infectious diseases research lab, and chair of the division of clinical microbiology at Mayo Clinic.

Apr 13, 2018

Heidi Rehm

Heidi Rehm last month became chief genomics officer in the Department of Medicine at Massachusetts General Hospital, where she is part of the Center for Genomic Medicine. In her new role, she will focus on the clinical implementation of genomics. Rehm remains medical director of the Broad Institute’s clinical research sequencing platform and an associate professor of pathology at MGH, Brigham and Women’s Hospital, and Harvard Medical School. She is also a leader and principal investigator of ClinGen, and a co-leader of the Broad Center for Mendelian Genomics. Previously, Rehm was the director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine.

Apr 13, 2018

Michael Murray

Michael Murray has become director for clinical operations in the Center for Genomic Health at Yale University School of Medicine. He joins Yale from the Geisinger Health System, where he was director of clinical genomics and was leading the GenomeFIRST return of results program, which is part of Geisinger’s MyCode Community Heath Initiative. In his new role at Yale, he will similarly focus on bringing clinical genomics to large patient cohorts.

Apr 12, 2018

Richard Kivel

BC Platforms announced today that it has appointed Richard Kivel as company chairman. Kivel is currently managing director at Graybella Captial and holds various director positions in the US and Europe.

Apr 11, 2018

Chris Callahan

PieranDx has named Chris Callahan chief commercial officer, where he will head sales, marketing, and business development efforts. Callahan joins the bioinformatics startup after serving as vice president for product strategy and business development for Sunquest Information Systems. He previously held a managerial-level position at health IT giant Cerner. St. Louis-based PieranDX is in growth mode, having raised $3 million in new funding in February and entered into a partnership with Cancer Genetics last month.

Apr 11, 2018

Kenneth Berlin

Rosetta Genomics President and CEO Kenneth Berlin is resigning from the company effective April 18 to pursue other opportunities. He will assist the company in a smooth transition with ongoing projects, the company said. Berlin joined Rosetta Genomics in November 2009 as president and CEO. Before that, he was worldwide general manager at Veridex, a Johnson & Johnson company. He joined J&J in 1994 and was its corporate counsel for six years, according to Rosetta Genomics' website. From 2001 to 2004, he was vice president of licensing and new business development in the pharmaceutical group at J&J, and from 2004 to 2007, he was worldwide VP of franchise development at Ortho Clinical Diagnostics, also a J&J company. 

Apr 10, 2018

James Mock

PerkinElmer has appointed James Mock as senior vice president and CFO, effective May 1. Mock will replace Andy Wilson as CFO. Wilson, who previously announced his retirement from PerkinElmer, will remain with the company as an advisor for an interim period to ensure a smooth integration, the firm said. Mock has served for nearly 20 years in a wide range of financial oversight capacities within General Electric, most recently as vice president of GE's corporate audit staff, where he worked on controllership reviews and operational excellence projects. 

Apr 10, 2018

David Rappaport

OraSure Technologies has appointed David Rappaport senior vice president of business development. He had been senior vice president, healthcare investment banking at Raymond James. Prior to that, Rappaport was a healthcare investment banker with Inverness Advisors, Theomas Weisel Partners, and SG Cowen. 

Apr 10, 2018

Dennis Shin

Precision oncology company Syapse has hired Dennis Shin as chief commercial officer. Shin, who has extensive experience with health system partnerships with and physician-focused IT systems, joins Syapse after 22 years at the Advisory Board Co., where he most recently was senior vice president of national and strategic accounts.

Apr 10, 2018

Karen Gripp, Peter Krawitz

FDNA has appointed Karen Gripp as CMO and Peter Krawitz as chief data science officer. The maker of the Face2Gene suite of next-generation phenotyping (NGP) applications said in a statement that their combined clinical, research, and development experience "will elevate the use and proven success of NGP technologies that capture, structure, and interpret complex physiological information." Gripp is chief of medical genetics at the AI duPont Hospital for Children and a professor of pediatrics at the Sidney Kimmel Medical College at Thomas Jefferson University. Krawitz is director of the Institute for Genomic Statistics and Bioinformatics at the University of Bonn in Germany and has been working with FDNA on a study called Prioritization of Exome Data By Image Analysis, or PEDIA, to determine the impact of phenotype and facial analysis on molecular interpretation.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.